Dr. David Samadi is one of the foremost surgeons of prostate cancer in the world. He is particularly enthusiastic about the uses of robotics in future surgeries. Samadi, who lives and works in New York, is the only surgeon who has performed a surgery using the SMART surgery technique via the da vinci robotic system. Samadi has said that the da vinci system is by far the most advanced tool for minimally invasive surgery. The current state of prostate surgery technology of any kind is a huge step up from the past traditional surgeries which required a large incision, usually resulted in lots of adverse side effects, and required much recovery time.
The now minimal incisions of the surgery mean the healing process will be much faster. Samadi says the new recuperation process now only takes one to three weeks. In addition (and most importantly to many) the da vinci system ensures that the nerves that control both the sexual system and the bladder are left whole and unharmed. He is a coveted speaker who speaks much as a valued member of both the American Urologic Association and the American Medical Association. He is also frequently invited to appear on Fox News.
So frequent, in fact, that it now takes place on a weekly basis. As a result, he is now considered a celebrity doctor. He is a huge encourager of testing for patients. He is especially so about the PSA (prostate specific antigen) test. These kinds of tests are conclusive proof about whether or not a patient requires prostate surgery. In his own practice, on average he will perform about 15 prostate surgeries a week. Because of his clear expertise in the field, he has become a very popular doctor. He has also become one of the highest-paid surgeons in the country. Samadi currently serves as the Chairman of Urology at Lenox Hill.
If you’re unfamiliar with Seattle Genetics, it is a biotechnology company Co-founded by Dr. Clay Siegall and a company, which has made it their mission to develop targeted therapy drugs. If you haven’t heard of this drug classification, it is pharmacotherapy aimed at treating patients who have been diagnosed with localized cancers and other diseases, that targets a specific area of the body. Many of the drug therapies developed by Seattle Genetics have been shown to significantly improve mortality rates, amongst those afflicted with serious diseases. In fact, Seattle Genetics recently secured FDA approval for Adcetris; an antibody-drug conjugate for those diagnosed with systemic anaplastic large cell lymphoma and Hodgkin lymphoma.
Prior to becoming the Co-founder of Seattle Genetics, Dr. Siegall served a Senior Research Investigator for Bristol-Myers Squibb, a global biopharmaceutical company. He maintained his role as Senior Research Investigator from 1991 to 1995 and later became the company’s Principal Scientist, before leaving the company in 1997, to pursue other endeavors, which led to Co-founding Seattle Genetics in 1998.
In addition to his industry experience, Dr. Siegall possesses an equally impressive education background; he is a George Washinton University alumnus, who earned a Ph.D. in Genetics, before going on to study at the University of Maryland where earned a Bachelor’s of Science degree, in Zoology. The impetus behind Dr. Siegall’s decision to pursue a career in biotechnology stems from a personal experience; in a candid interview with inspirey.com, a platform that conducts exclusive interviews with entrepreneurs and executives, Dr. Siegall describes having witnessed a cancer treatment regimen that nearly resulted in a patient’s death. This experience led him down a path of drug development that would serve as an alternative to traditional cancer treatment regimens including radiation.
Dr. Siegall’s efforts in the biotechnology space have earned him considerable praise; he was named Alumnus of the year by is his alma mater, the University of Maryland, and he has also received the Pacific Northwest Ernst and Young Entrepreneur of the year, award. Although he is busy with the day to day operations at Seattle Genetics, Dr. Siegall still manages to find time to fulfill Director roles; he is the Director for the Washington Biotechnology and Biomedical Association and also, sits on the editorial board for multiple scientific journals.